Antipodes Partners’s Henry Schein HSIC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-632
Closed -$41.9K 139
2025
Q3
$41.9K Buy
632
+46
+8% +$3.18K ﹤0.01% 97
2025
Q2
$42.8K Buy
+586
New +$40.3K ﹤0.01% 89
2024
Q1
Sell
-316
Closed -$23K 74
2023
Q4
$23K Hold
316
﹤0.01% 72
2023
Q3
$23K Hold
316
﹤0.01% 67
2023
Q2
$25K Sell
316
-104
-25% -$8.22K ﹤0.01% 62
2023
Q1
$34K Sell
420
-395
-48% -$32.2K ﹤0.01% 56
2022
Q4
$65K Buy
+815
New +$61.7K ﹤0.01% 53

Other funds holding HSIC

Antipodes Partners's HSIC Position: Q4 2025 in Review

Antipodes Partners sold out of Henry Schein (HSIC) in Q4 2025, closing a stake of 632 shares — an estimated $41.9K sold.

Antipodes Partners first reported a position in HSIC in Q4 2022 and held it in 7 quarters. The position peaked at $65K in Q4 2022. 544 funds tracked by Wall St. Rank hold HSIC as of Q4 2025.

  • Antipodes Partners reported no remaining Henry Schein position as of Q4 2025 after selling out during the quarter.
  • Antipodes Partners sold 632 Henry Schein shares in Q4 2025, an estimated $41.9K.
  • Antipodes Partners first reported a position in Henry Schein in Q4 2022 and held it in 7 quarters.
  • Antipodes Partners's Henry Schein position peaked at $65K in Q4 2022.
  • 544 funds tracked by Wall St. Rank held Henry Schein as of Q4 2025.

Based on Antipodes Partners's 13F filing for Q4 2025, filed 5 Feb 2026.